|
Volumn 21, Issue 6, 2003, Pages 969-970
|
Dendritic Cell Vaccines - Hopeful or Hopeless?
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ADJUVANT;
CANCER VACCINE;
CYTOKINE;
DNA VACCINE;
FLT3 LIGAND;
MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;
MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;
PEPTIDE DERIVATIVE;
PROTEIN DERIVATIVE;
TUMOR ANTIGEN;
ACTIVE IMMUNIZATION;
ANTIGEN PRESENTATION;
ANTIGEN PRESENTING CELL;
CANCER;
CANCER IMMUNOTHERAPY;
CANCER REGRESSION;
CELL FUNCTION;
CELL INTERACTION;
CELL MATURATION;
CELL POPULATION;
CELL STIMULATION;
CELLULAR IMMUNITY;
CLINICAL TRIAL;
DENDRITIC CELL;
DRUG SAFETY;
EDITORIAL;
EFFECTOR CELL;
GENETIC ENGINEERING;
HUMAN;
HUMORAL IMMUNITY;
IMMUNE RESPONSE;
LEUKAPHERESIS;
NATURAL KILLER CELL;
OUTCOMES RESEARCH;
PRIORITY JOURNAL;
SIDE EFFECT;
T LYMPHOCYTE;
TECHNIQUE;
TUMOR CELL;
VACCINATION;
ANTIGENS, NEOPLASM;
CANCER VACCINES;
DENDRITIC CELLS;
HLA ANTIGENS;
HUMANS;
IMMUNIZATION;
LEUKAPHERESIS;
NEOPLASMS;
|
EID: 0347988113
PISSN: 07357907
EISSN: None
Source Type: Journal
DOI: 10.1081/CNV-120025101 Document Type: Editorial |
Times cited : (6)
|
References (8)
|